Novo Nordisk Shares Under Pressure as US Pricing Deal and Acquisition Battle Intensify

Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a significant pricing agreement with US authorities and an escalating bidding war for a key biotechnology firm. The developments have sparked concerns among investors about the company’s ability to balance revenue pressures with strategic expansion needs.

In a move that will substantially reduce patient expenses, Novo Nordisk and competitor Eli Lilly have reached a settlement with the US government regarding pricing for GLP-1 medications, including the weight-loss treatment Wegovy. The arrangement, confirmed on Thursday, November 6, will lower monthly costs for Medicare, Medicaid, and self-paying patients to a range of $149 to $350. Previously, these medications carried price tags between $500 and Read more...